Home - Products - GPCR/G Protein - Glucagon Receptor - V-0219

V-0219

CAS No. 878453-71-5

V-0219( —— )

Catalog No. M28512 CAS No. 878453-71-5

V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	191	In Stock
10MG	327	In Stock
25MG	604	In Stock
50MG	906	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

V-0219
Note

Research use only, not for human use.
Brief Description

V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
Description

V-0219 is a positive allosteric modulator of GLP-1 and can be used in studies about obesity-associated diabetes.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

GPCR/G Protein
Target

Glucagon Receptor
Recptor

——
Research Area

——
Indication

——

Chemical Information

CAS Number

878453-71-5
Formula Weight

410.43
Molecular Formula

C20H25F3N4O2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : 100 mg/mL (243.65 mM)
SMILES

FC(F)(F)C=1C=CC(=CC1)C2=NOC(=N2)CN3CCCC(C3)CN4CCOCC4
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

MK-3577

A potent, oral active glucagon receptor antagonist blocking the glucagon effect for the treatment of T2DM.
Semaglutide Acetate

Semaglutide Acetate is an agonist of a glucagon-like peptide 1 (GLP-1) receptor and can be used in studies about the treatment of type 2 diabetes.
Bay 55-9837

Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists.

Sign In Join Free